Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Antibody fragment expression and purification.

Dimitrova D, Choudhry V, Broder CC.

Methods Mol Biol. 2009;525:491-8, xiii. doi: 10.1007/978-1-59745-554-1_25.

2.

Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.

Zhu Z, Dimitrov AS, Chakraborti S, Dimitrova D, Xiao X, Broder CC, Dimitrov DS.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66. Review.

PMID:
16441209
3.

Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.

Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS.

Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Review.

PMID:
23575729
4.

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.

van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J.

J Virol. 2005 Feb;79(3):1635-44.

6.

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.

Liang MF, Du RL, Liu JZ, Li C, Zhang QF, Han LL, Yu JS, Duan SM, Wang XF, Wu KX, Xiong ZH, Jin Q, Li DX.

Biomed Environ Sci. 2005 Dec;18(6):363-74.

PMID:
16544518
7.

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.

Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM.

J Infect Dis. 2005 Feb 15;191(4):507-14.

PMID:
15655773
8.

Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach.

Flego M, Di Bonito P, Ascione A, Zamboni S, Carattoli A, Grasso F, Cassone A, Cianfriglia M.

BMC Infect Dis. 2005 Sep 19;5:73.

9.

Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R.

J Virol. 2008 Apr;82(7):3220-35. doi: 10.1128/JVI.02377-07.

11.

Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.

Zhang X, Wang J, Wen K, Mou Z, Zou L, Che X, Ni B, Wu Y.

Viral Immunol. 2009 Dec;22(6):407-15. doi: 10.1089/vim.2009.0046.

PMID:
19951177
13.

Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Kang X, Yang BA, Hu Y, Zhao H, Xiong W, Yang Y, Si B, Zhu Q.

Clin Vaccine Immunol. 2006 Aug;13(8):953-7.

14.

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A.

J Immunol. 2002 Jul 1;169(1):595-605.

16.

Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).

Chou TH, Wang S, Sakhatskyy PV, Mboudjeka I, Lawrence JM, Huang S, Coley S, Yang B, Li J, Zhu Q, Lu S.

Virology. 2005 Mar 30;334(1):134-43. Erratum in: Virology. 2005 Jun 20;337(1):204. Mboudoudjeck, Innocent [corrected to Mboudjeka, Innocent].

17.

Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.

Wang X, Ni B, Du X, Zhao G, Gao W, Shi X, Zhang S, Zhang L, Wang D, Luo D, Xing L, Jiang H, Li W, Jiang M, Mao L, He Y, Xiao Y, Wu Y.

Antivir Ther. 2005;10(5):681-90.

PMID:
16152762
18.

A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage.

Lee YC, Leu SJ, Hung HC, Wu HH, Huang IJ, Hsieh WS, Chiu WT, Hsieh MS, Cheng TF, Yang YY.

Vet Immunol Immunopathol. 2007 May 15;117(1-2):75-85.

PMID:
17360045
19.
20.

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.

Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, Corbett CR, Andonov A.

MAbs. 2010 Jan-Feb;2(1):53-66.

Supplemental Content

Support Center